Analyst consensus rating
BioMarin Pharmaceutical Analyst Rating: Buy
Direct answer
BioMarin Pharmaceutical's consensus rating is Buy.
27 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $91.56.
Forecast evidence checked October 27, 2026.
Get free BioMarin Pharmaceutical email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $55.35
- Average price target
- $91.56
- High price target
- $122.00
- Low price target
- $60.00
- Low target gap
- +8.4%
- Target upside
- +65.4%
- High target gap
- +120.4%
- Target range width
- 112%
- Consensus rating
- Buy
- Analysts
- 27
- Evidence date
- October 27, 2026
- Valid through
- November 3, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for BioMarin Pharmaceutical?
BioMarin Pharmaceutical has a verified Buy consensus. The same dataset has an average price target of $91.56.
How far are BioMarin Pharmaceutical's low and high targets from the recorded price?
The low target implies +8.4%, while the high target implies +120.4%.
How many analysts are included in BioMarin Pharmaceutical's consensus?
The verified consensus includes 27 analysts.
How is BioMarin Pharmaceutical's target upside or downside calculated?
The average target of $91.56 is divided by the recorded price of $55.35, then one is subtracted to produce +65.4%. This does not guarantee a future return.
When was BioMarin Pharmaceutical's analyst forecast verified?
The data was verified on 2026-10-27. The dataset is valid through 2026-11-03.